AdWorld Businesses for Sale
Visit World Businesses for Sale
Thinking of selling your business? Buy or sell a business locally, nationally or worldwide. 10% off with code AWN10.
The immune cells that small cell lung cancer can't hide from (WEHI, Cancer Cell; lab results, not yet a treatment)
The full story behind my Short: WEHI researchers found that gamma delta T cells can recognise and kill small cell lung cancer even when it hides from the usual immune cells. In trial data, patients with more of these cells tended to live longer, and two approved drugs boosted their killing in the lab.
The short version
Scientists at WEHI in Melbourne have found an immune cell that can kill small cell lung cancer (SCLC), one of the deadliest lung cancers, even while it hides. SCLC dodges the usual killer T cells by switching off MHC-I, the signal they need to recognise it, and fewer than 7% of patients survive five years. Gamma delta T cells don't need that signal. In lab-grown mini tumours made from patients' samples, gamma delta T cells from the same patients' blood recognised and killed the cancer cells. Two drugs that are already approved made them stronger in the lab: zoledronate (an osteoporosis and cancer-related bone disease drug) increased their numbers and recognition, and tarlatamab (approved for SCLC) brought them into closer contact with the tumour. In data from two major immunotherapy trials (IMpower133 and CASPIAN), patients whose tumours had more of these cells tended to live longer. Caveat: the survival link is an association and a trend, and the drug boost was shown in lab models, not yet tested in patients (Ng, Sutherland et al., Cancer Cell, 2026).
<7%of people with small cell lung cancer survive five years [1][2]
MHC-Ithe signal SCLC switches off to hide from killer T cells; gamma delta T cells recognise it without it, via BTN2A1 [3]
15.4 vs 10.8months median survival, high vs low gamma delta T cell signal, IMpower133 immunotherapy arm (a trend, not proof) [3]
Lab onlyzoledronate + tarlatamab boosted killing in lab models, not yet in patients [2][3]
What they found
Small cell lung cancer is the most aggressive form of lung cancer, and fewer than 7% of patients survive five years [1][2]. Immunotherapy helps only some patients, partly because SCLC switches off MHC-I, the molecule that conventional killer (CD8) T cells need to recognise tumour cells [3]. Using single-cell analysis of patient biopsy samples, Dr Jin Ng, Prof Kate Sutherland and colleagues at WEHI found gamma delta T cells inside the tumours, and these cells kept a cancer-killing profile [3]. The main subtype studied (Vδ2+) recognised and killed SCLC through a molecule called BTN2A1, independent of MHC-I [3].
The team then went back to data from two practice-changing immunotherapy trials, IMpower133 and CASPIAN. In patients receiving anti-PD-L1 immunotherapy, a high gamma delta T cell signal was linked to longer survival: in IMpower133 (271 patients), median overall survival was 15.4 months with a high signal versus 10.8 months with a low one. The paper describes this as a trend towards improved survival; it is an association in trial data, not proof that the cells caused the difference [3].
To test the cells directly, the researchers grew “mini tumours” from samples donated through the Victorian Cancer Biobank with the Royal Melbourne Hospital. Gamma delta T cells from the patients' own blood were highly effective at killing the SCLC cells [2]. Two approved drugs amplified the effect: zoledronate, approved for osteoporosis and cancer-related bone disease, increased the number of gamma delta T cells and their ability to recognise the tumours, and tarlatamab, approved for SCLC, acted “like a magnetic force” bringing the immune cells into contact with the cancer [2][3]. The authors note they did not test this in a living (humanised mouse) model [3].
Watch the Short
AI voice note: the narration in this Short is my own voice, cloned with AI.
About this page
The survival link comes from re-analysing earlier trial data: patients with more gamma delta T cells “trended toward” longer survival on immunotherapy (15.4 vs 10.8 months median in IMpower133). That is an association, not proof. The tumour-killing and drug-boost results are from laboratory models (patient-derived mini tumours and cell co-cultures), not patients. The paper was published online on 18 September 2026; WEHI's release is dated 15 October 2026 and ScienceDaily reported it on 22 October 2026. All photos are illustrative, from Wikimedia Commons (credited below).
Why it matters
- A new route. Gamma delta T cells could help patients whose tumours hide from conventional T cells [2].
- Existing drugs. Because both drugs are already approved, and therapies that grow and re-infuse gamma delta T cells already exist, the team hopes to move quickly towards trials [2].
- Early days. The drug results are from lab models; whether they help patients still has to be tested in clinical trials [2][3].
Full narration (transcript)
Scientists found an immune cell that can kill a deadly lung cancer, even while it hides. Small cell lung cancer dodges the usual immune cells, and under 7 percent of patients survive five years. Now a team at WEHI in Melbourne has found a different defender: gamma delta T cells. These cells don't need the signal the cancer switches off, so they can still recognise the tumour. In lab-grown mini tumours from patients, their own gamma delta T cells killed the cancer cells. But here's where it gets interesting. Two drugs that are already approved made them even stronger. An osteoporosis drug boosted their numbers, and a lung cancer drug pulled them onto the tumour. In two major immunotherapy trials, patients with more of these cells tended to live longer. The caveat: that's only a trend, and the drug boost was lab-only, not yet tested in patients. It's published in Cancer Cell. Next, the team wants to turn this into new immunotherapies. Follow the link to the main website for much deeper information.
Sources
- [1] Walter and Eliza Hall Institute (2026). “Scientists discover a hidden immune weapon against deadly lung cancer.” ScienceDaily, 22 October 2026. sciencedaily.com
- [2] WEHI (2026). “Invisible no more: New treatment avenue unlocked for deadliest lung cancer.” WEHI news, 15 October 2026. wehi.edu.au
- [3] Ng, J., You, Y., Zhang, T.Z., Hess, J.B., Best, S.A., … Steinfort, D. & Sutherland, K.D. (2026). “γδ T cells modulate anti-tumor immunity in small cell lung cancer.” Cancer Cell 44(10): 1963–1980. DOI 10.1016/j.ccell.2026.08.015 (open access, CC BY 4.0). doi.org
Credits
Images via Wikimedia Commons (illustrative): Killer T cells surround a cancer cell.png (The National Institutes of Health, Public domain); WEHI2023.jpg (Sgroey, CC0); Organoid (NIH BioArt 399 - 633173).png (Courtesy of NIAID Ryan Kissinger, Public domain); X-ray chest cancer.jpg (X-ray(Chest)Cancer.jpg: unknown derivative work: Anassagora (talk), Public domain); Small cell lung cancer - cytology.jpg (Nephron, CC BY-SA 3.0). Sketches and animation: my own. Narration: AI clone of Nasper Mushonga's own voice (Chatterbox TTS by Resemble AI, MIT licence), used with his consent.